Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2015-04-29

FDA Approved: AKYNZEO — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)

View source ↗

Summary

FDA approved a supplemental application for AKYNZEO (netupitant and palonosetron) to modify its labeling for prevention of chemotherapy-induced nausea and vomit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Akynzeo (netupitant/palonosetron)

Snippet

SUPPL AP for AKYNZEO (NETUPITANT AND PALONOSETRON)